Curated news and analysis on clinical trials, drug approvals, and medical research.
Mexican authorities killed Nemesio Oseguera Cervantes, known as 'El Mencho,' founder of the Jalisco New Generation Cartel, in a Sunday military operation aided by U.S. intelligence. The operation sparked widespread violence across western Mexico.
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
The American Psychiatric Association released a roadmap for the future DSM in January 2026, proposing to incorporate biomarkers and rename the manual to reflect scientific scope. A new conceptual framework suggests using electrical and chemical signals to explain mental disorders and human intelligence.
Savara Inc. announced the FDA has accepted its resubmitted Biologics License Application for MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis, with Priority Review granted and a target decision date of August 22, 2026.
Jammu and Kashmir government plans comprehensive Biotechnology Policy to leverage the Union Territory's rich biodiversity and medicinal plant wealth for India's growing bio-economy, with Rs 84.66 crore investment in two biotech parks.
New research shows the nervous system contributes to pancreatic cancer development before tumors fully form, with nerve fibers and support cells creating a self-sustaining loop that promotes cancer growth. Blocking nerve activity reduced tumor growth by nearly 50% in experiments.
BioAsia 2026 in Hyderabad attracted over 4,000 delegates and 500 companies, featuring AI-driven drug discovery platforms and showcasing Indian biotech innovations including BioVaram's regenerative medicine breakthrough.
Recent research explores plant-based diets' association with breast cancer risk, disparities in care for Black women in Canada, and survival outcomes for young women with breast cancer in Latin America.
CAR-T cell therapy engineering advances at Tandem 2026 focus on reducing toxicity and improving access, while McGill researchers develop targeted nanoparticle immunotherapy for lymph node metastases with fewer side effects.
Soleno Therapeutics provided updates on its VYKAT XR commercial launch for Prader-Willi syndrome, reporting reimbursement progress across nearly 48 Medicaid programs and over 600 prescribers, while European regulatory review continues for approximately 9,500 additional patients.
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
Multiple television personalities have openly discussed their use of GLP-1 medications for weight loss, with some experiencing facial changes known as "Ozempic face" characterized by volume loss and more pronounced features.
The FDA approved KEYTRUDA and its subcutaneous QLEX formulation for platinum-resistant ovarian cancer, marking the first PD-1 inhibitor cleared for this patient population based on Phase 3 results.
With semaglutide and tirzepatide shortages resolved, the FDA is cracking down on compounded GLP-1 medications. Concerns emerge over 33 unique compounded formulations with limited safety data and nonstandard delivery methods.
MannKind Corporation has enrolled the first pediatric patient in its INHALE-1ST trial evaluating Afrezza inhaled insulin in children with type 1 diabetes. The FDA is reviewing a supplemental Biologics License Application with a decision expected by May 29, 2026.
Zydus Lifesciences Limited received final FDA approval for Ammonium Lactate Cream, 12%, a generic of Lac-Hydrin Cream. The topical prescription medication treats xerosis and ichthyosis vulgaris, with annual U.S. sales of $15 million.
Oncolytics Biotech announced FDA Fast Track Designation for pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant metastatic colorectal cancer, driving shares up 19.7%.
Alphamab Oncology dosed the first patient in its Phase III trial of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, for HER2-positive advanced colorectal cancer on February 14, 2026.
Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025, with successful phase 3 trials for cancer drug Jaypirca, next-gen obesity medicine retatrutide, and oral GLP-1 orforglipron, while Alzheimer's drug Kisunla showed cognitive decline benefits.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
